NYSE:ABBV - AbbVie Inc.
$80.57
 $0.05
+0.06%
2:20PM EDT
2019-02-15
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ABBV     avg for
industry  
  avg for
sector  
42 stocks weight:  53. 16   0. 00   0. 00  
42 stocks rank:  2. 65 K 1. 86 K 1. 09 K
# analyst opinions:  17. 00   14. 92   14. 43  
mean recommendation:  2. 70   1. 91   1. 93  


ex-dividend date:     2019-01-13
dividend rate:  4. 28   1. 31   1. 55  
dividend yield:  5. 41 % 1. 78 % 1. 74 %
target price low:  71. 00   88. 97   117. 82  
target price avg:  93. 88   115. 19   141. 96  
target price high:  130. 00   143. 40   163. 16  
1-yr high:  121. 54   124. 30   142. 77  
last close:  80. 52   101. 85   127. 84  
50-day avg:  85. 31   98. 27   122. 46  
200-day avg:  92. 05   99. 72   122. 70  
1-yr low:  77. 14   78. 19   100. 16  
volume:  4. 60 M 2. 38 M 4. 64 M
50-day avg volume:  6. 96 M 3. 31 M 4. 94 M
200-day avg volume:  7. 06 M 3. 23 M 4. 28 M

1-day return:  -0. 33 % 0. 22 % 0. 48 %
this week return:  1. 07 % 1. 77 % 2. 01 %
12-wk return:  -5. 97 % 6. 56 % 3. 33 %
52-wk return:  -29. 27 % -2. 23 % 14. 35 %

enterprise value (EV):  152. 27 B 55. 17 B 104. 51 B
market cap:  121. 04 B 49. 01 B 96. 46 B
EBITDA:  13. 99 B 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  10. 88   -91. 79   2. 29  
enterprise/revenue (EV/R):  4. 65   29. 84   23. 39  
total revenue:  32. 75 B 11. 28 B 40. 22 B
total debt:  41. 22 B 13. 73 B 16. 57 B
net income (common):  5. 69 B 2. 37 B 3. 58 B

shares outstanding:  1. 50 B 607. 99 M 1. 22 B
shares:  1. 50 B 605. 53 M 1. 15 B
shares short:  28. 08 M 11. 62 M 12. 55 M
shares short prior month:  30. 86 M 11. 95 M 13. 44 M
short ratio:  3. 84   4. 82   3. 10  
short % of float:  2. 02 % 6. 19 % 2. 82 %
total cash/share:  5. 84   12. 02   11. 46  
total cash:  8. 79 B 7. 41 B 7. 37 B

book value:  -1. 94   14. 43   28. 26  
price/book:  -41. 46   -1. 57   -2. 97  
gross profits:  25. 04 B 8. 28 B 18. 09 B
operating margins:  37. 34 % -458. 01 % -642. 83 %
EBITDA margins:  42. 73 % 13. 81 % 22. 47 %
profit margins:  17. 36 % 6. 57 % 9. 92 %
gross margins:  76. 44 % 49. 33 % 54. 53 %

1-yr max volatility:  -12. 76 % --- ---
1-yr mean volatility:  -0. 10 % 0. 01 % 0. 06 %

1-yr EPS:  3. 66   3. 03   4. 09  
forward EPS:  9. 52   4. 33   6. 99  
P/E:  22. 00   6. 11   26. 91  
forward P/E:  8. 37   8. 38   10. 48  
PE/G:  3. 01   0. 37   5. 61  
growth:  7. 30 % 683. 72 % 104. 79 %
earnings high:  2. 06   1. 27   1. 66  
earnings avg:  2. 04   1. 01   1. 53  
earnings low:  1. 98   0. 76   1. 40  
revenue high:  7. 92 B 2. 86 B 11. 19 B
revenue avg:  7. 80 B 2. 78 B 10. 84 B
revenue low:  7. 66 B 2. 67 B 10. 64 B
return on equity:  522. 70 % 107. 48 % 27. 82 %
revenue growth:  7. 30 % 648. 36 % 97. 70 %
revenue/share:  21. 19   14. 68   59. 83  

beta (1yr vs S&P500):  0. 74   1. 21   0. 93  
sharpe (1yr):  -0. 80   0. 06   0. 98  

held % insiders:  0. 07 % 6. 46 % 3. 21 %
held % institutions:  72. 20 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : ABBV
.   + 12.633 =        12.633 :: INITIAL WEIGHT
.     + 88.5 =       101.134 :: inverse volume-to-price addition
.  + 440.249 =       541.383 :: spline projection addition
.  + 933.714 =      1475.097 :: notable performance addition
.   - 87.144 =      1387.953 :: poor performance penalty
.    x 0.874 =      1213.537 :: one-year gains+dividend factor
.    x 2.003 =      2430.789 :: 13 weeks' performance factor
.    x 1.492 =      3627.925 :: industry recommendation factor
.    x 1.034 =      3752.677 :: symbol recommendation factor
.    x 1.156 =      4337.414 :: EV/R factor
.      x 1.8 =      7807.437 :: return on equity factor
.      x 2.2 =     17180.034 :: revenue growth factor
.    x 1.123 =     19287.729 :: short ratio factor
.    x 1.585 =       30578.3 :: price-to-book factor
.    x 1.296 =     39622.459 :: EBITDA multiple factor
.    x 2.632 =    104267.812 :: P/E weight
.    x 0.759 =      79136.22 :: PE/G factor
.    x 1.693 =    133963.425 :: beta factor
.    x 0.803 =    107581.982 :: sharpe factor
.    x 0.966 =    103882.796 :: target low factor
.    x 1.136 =    117987.817 :: target mean factor
.    x 1.078 =    127236.931 :: target high factor
.    x 1.066 =    135585.303 :: industry 12-weeks return
.    x 0.999 =    135448.918 :: overall "drift" factor
.    x 0.999 =    135377.197 :: largest single-day jump factor
.     x 1.01 =    136729.562 :: mean volatility factor
.    x 1.098 =    150178.566 :: 42-day mean volatility factor
.      x 1.0 =    150188.647 :: factor hist industry gain for week 06
.   cubeRoot =        53.155 :: reduced for readability
.                     53.155 :: FINAL WEIGHT for NYSE:ABBV


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org